Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012–2015

Mark Stuntz⁎, Brent Bernstein

Deerfield Institute, New York, NY, United States

A R T I C L E  I N F O

Article history:
Received 13 October 2016
Received in revised form 6 December 2016
Accepted 26 December 2016
Available online 28 December 2016

Keywords:
Aspirin
Epidemiology
Cardiovascular disease

A B S T R A C T

Aspirin therapy has been shown to be an effective prevention measure to reduce the risk of new or recurring cardiovascular events. The aim of this study was to provide an epidemiological analysis of low-dose aspirin use for primary and secondary CVD prevention from 2012 to 2015. Estimates of self-reported low-dose aspirin use for primary and secondary CVD prevention were obtained from the National Health Interview Survey for the years 2012–2015. Temporal changes in the prevalence of aspirin use for primary and secondary CVD prevention were assessed using logistic regression. During 2012–2015, 23.3% of respondents self-reported as taking aspirin for primary CVD prevention, decreasing from 23.7% in 2012 to 21.8% in 2015. Also during this period, 8.4% self-reported as taking aspirin for secondary CVD prevention, decreasing from 8.9% in 2012 to 8.2% in 2015. Overall, the prevalence of aspirin use for CVD prevention declined from 32.6% in 2012 to 30.0% in 2015. This study shows that over 30% of the adult population self-reports as taking low-dose aspirin for primary or secondary CVD prevention. Despite the decline in this prevalence over the previous four years, aspirin therapy remains a highly-utilized means of preventing CVD.

© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Cardiovascular disease (CVD) produces immense health and economic burdens in the United States. CVD is the leading cause of death, accounting for 30.8% of all deaths in the United States in 2013 (Mozaffarian et al., 2016). For 2011 to 2012, the estimated annual direct costs for CVD were $193.1 billion. By comparison, cancer, the second leading cause of death, had an estimated direct cost of $88.7 billion. CVD also accounted for an additional $123.5 billion in indirect costs from lost future productivity, bringing the total attributable cost to $316.6 billion (Mozaffarian et al., 2016).

Aspirin is one of the oldest drugs in use, dating back to the times of the ancient Greeks when the bark of the willow tree became known for its anti-inflammatory properties. Acetylsalicylic acid, the modern version of aspirin, has been in constant use since being introduced to the public in 1904 (Ittaman et al., 2014; Fuster and Sweeney, 2011). Later studies demonstrated the anti-thrombotic effects of low-dose aspirin regimens (Miner and Hoffhines, 2007).

Aspirin has been shown to be effective as a preventive therapy among patients at risk of developing CVD (primary prevention) as well as among patients who suffer from one or more CVD events (secondary prevention) (Baigent et al., 2009). The United States Preventive Services Task Force (USPSTF) currently recommends low-dose aspirin use for primary CVD prevention (Bibbings-Domingo and US Preventive Services Task Force, 2016) and the American Heart Association and American College of Cardiology Foundation jointly recommend low-dose aspirin use for secondary CVD prevention (Smith et al., 2011).

Previous cross-sectional studies have examined the use of aspirin and CVD prevention. The aim of this study was to provide an accurate and up-to-date epidemiological analysis of the use of low-dose aspirin for both primary and secondary CVD prevention from 2012 to 2015.

2. Methods

This study utilized data from the 2012–2015 National Health Interview Survey (NHIS), one of the major data collection programs of the National Center for Health Statistics (NCHS) which is part of the Centers for Disease Control and Prevention (CDC). The NHIS is the principal source of information on a broad range of health topics for the civilian noninstitutionalized population and has been conducted continuously since 1957. The sampling plan follows a multistage area probability design that permits the representative sampling of households and...
Annual trends in the prevalence of aspirin use for primary and secondary CVD prevention were examined by age (age-specific prevalence), sex, race/ethnicity, geographic region, household income, health insurance status, BMI, and education (age-adjusted prevalences). Age-adjusted prevalences were calculated using the year 2000 US population as the standard (direct method) (Klein and Schoenborn, 2001). Age-specific and age-adjusted prevalences were estimated with corresponding 95% confidence intervals (CIs). The CSLOGISTIC procedure was used to estimate the average rates of change over time, and trends were tested by evaluating the parameter for years as a continuous variable. Trend significance was assessed via a Wald F test with $\alpha = 0.05$.

This study was approved by the Deerfield Institute Research Review Committee and deemed to be in full compliance of HIPAA (Health Insurance Portability and Accountability Act) guidelines, as it did not collect protected private health information that could be used to identify participants. Survey participation in the NHIS is voluntary and the confidentiality of responses is assured under Section 308(d) of the Public Health Service Act (National Center for Health Statistics, 2016).

### 3. Results

The 2012–2015 NHIS included a total of 90,558 adults over the age of 40. Demographic characteristics of the sample are presented in Table 1. During 2012–2015, 12.3% (95% CI: 12.0%–12.6%) of adults self-reported as having at least one CVD. Coronary heart disease was the most common CVD, prevalent among 7.1% (95% CI: 6.9%–7.3%) of adults, followed by myocardial infarction (5.0%; 95% CI: 4.8%–5.2%), stroke (4.1%; 95% CI: 4.0%–4.3%), and angina pectoris (3.0%; 95% CI: 2.8%–3.1%).

Table 2 describes the prevalence of aspirin use for primary CVD prevention by select demographic characteristics. Aspirin use prevalence was highest among adults aged 65 years and older; males; non-Hispanic whites; those living in the Midwest region; those with annual household income of $100,000 and over; those with health insurance; obese; those with at least some college education; and those with four or more modifiable CVD risk factors.

The overall age-adjusted prevalence of aspirin use for primary CVD prevention was 22.1% (95% CI: 21.9%–22.3%), decreasing from 22.8% in 2012 to 20.4% in 2015. Based on the complex samples logistic regression model, this corresponds to an average annual rate of change of $-2.7\%$ ($p = 0.003$). All age groups saw significant decreases in prevalence, though the 40–49 years age group saw the greatest decline (−7.9% average annual rate of change; $p = 0.001$). While the majority of the select demographics saw a decline in aspirin use for primary CVD prevention,

### Table 1

Characteristics and demographics of adults 40 years of age and older by year of NHIS data.

| Sample size | 2012 % (95% CI) | 2013 % (95% CI) | 2014 % (95% CI) | 2015 % (95% CI) | 2012–2015 total % (95% CI) |
|-------------|----------------|----------------|----------------|----------------|-----------------------------|
| **Age group** |                |                |                |                |                             |
| 40–49       | 29.1% (28.4–29.8) | 28.5% (27.7–29.3) | 27.9% (27.0–28.7) | 27.2% (26.3–28.2) | 28.2% (27.7–28.6) |
| 50–64       | 41.9% (41.1–42.8) | 41.9% (41.0–42.7) | 41.9% (40.9–42.8) | 41.8% (40.8–42.7) | 41.8% (41.4–42.4) |
| ≥65         | 29.0% (28.2–29.8) | 29.6% (28.9–30.4) | 30.3% (29.4–31.2) | 31.0% (30.1–32.0) | 30.0% (29.5–30.5) |
| **Sex**     |               |                |                |                |                             |
| Male        | 47.3% (46.4–48.1) | 47.6% (46.7–48.5) | 47.3% (46.4–48.3) | 47.2% (46.4–48.2) | 47.4% (46.9–47.8) |
| Female      | 52.7% (51.9–53.6) | 52.4% (51.5–53.1) | 52.7% (51.7–53.6) | 52.7% (51.8–53.6) | 52.6% (52.2–53.1) |
| **Race**    |               |                |                |                |                             |
| Non-Hispanic white | 71.9% (71.1–72.8) | 71.4% (70.6–72.3) | 70.8% (69.9–71.7) | 70.0% (69.0–70.9) | 71.0% (70.4–71.7) |
| Non-Hispanic black | 10.6% (10.0–11.2) | 10.6% (10.0–11.2) | 10.7% (10.1–11.3) | 10.9% (10.3–11.5) | 10.7% (10.3–11.1) |
| Hispanic    | 11.2% (10.6–11.8) | 11.6% (10.9–12.2) | 11.8% (11.2–12.4) | 12.1% (11.5–12.7) | 11.7% (11.2–12.1) |
| Other       | 6.2% (5.8–6.7) | 6.4% (6.0–6.9) | 6.7% (6.3–7.2) | 7.0% (6.5–7.5) | 6.6% (6.3–6.9) |
| **CVD prevalence** |         |                |                |                |                             |
| Coronary heart disease | 7.4% (7.0–7.8) | 7.5% (7.1–7.9) | 6.5% (6.1–6.9) | 7.1% (6.7–7.6) | 7.1% (6.9–7.3) |
| Angina pectoris | 3.0% (2.7–3.3) | 3.1% (2.8–3.4) | 2.8% (2.5–3.1) | 3.0% (2.7–3.3) | 3.0% (2.8–3.1) |
| Myocardial infarction | 5.1% (4.8–5.5) | 5.0% (4.7–5.3) | 4.9% (4.5–5.3) | 4.9% (4.5–5.3) | 5.0% (4.8–5.2) |
| Stroke      | 4.1% (3.8–4.5) | 4.3% (3.9–4.6) | 4.0% (3.7–4.3) | 4.1% (3.8–4.4) | 4.1% (4.0–4.3) |
| ≥1 CVD      | 12.7% (12.2–13.3) | 12.7% (12.2–13.2) | 11.7% (11.1–12.3) | 12.1% (11.5–12.7) | 12.3% (12.0–12.6) |
there was a significant increasing trend in prevalence among non-Hispanic blacks (5.1% average annual rate of change; \( p = 0.002 \)) and those with less than high school education (12.0% average annual rate of change; \( p = 0.002 \)).

Table 3 shows the prevalence of aspirin use for secondary CVD prevention. Aspirin use prevalence was highest among adults aged 65 years and older; males; non-Hispanic blacks; those living in the Midwest region; those with household annual income $\leq \$35,000; those with health insurance; obese; and those with less than high school education.

The overall age-adjusted prevalence of aspirin use for secondary CVD prevention was 8.0% (95% CI: 7.9%-8.1%), declining from 8.6% in 2012 to 7.6% in 2015. This corresponds to an average annual rate of change of \(-3.6\%\) (\( p = 0.015 \)). Similar to the primary CVD prevention population, the prevalence of aspirin use for secondary CVD prevention declined across the majority of the select demographics. Adults without health insurance saw the greatest decline in aspirin use prevalence for secondary CVD prevention (\(-17.2\%\) average annual rate of change; \( p = 0.006 \)). Trends among all demographics with positive average annual rates of change were not statistically significant.

4. Discussion

Low-dose aspirin use for primary CVD prevention is currently recommended by the USPSTF (Bibbins-Domingo and US Preventive Services Task Force, 2016), while the American Heart Association and American College of Cardiology Foundation (AHA/ACCF) jointly recommend low-dose aspirin use for secondary CVD prevention (Smith et al., 2011). This study shows that >30% of adults over the age of 40 self-report as taking low-dose aspirin for primary or secondary CVD prevention. Extrapolating to the US Census Bureau’s 2016 population estimates (United States Census Bureau, 2016), this results in approximately 35.8 million primary CVD prevention patients and 12.9 million secondary CVD prevention patients. However, we found that the prevalences of aspirin use for both primary and secondary CVD prevention have declined over the previous four years, despite the USPSTF and AHA/ACCF recommendations. The only selected demographics that saw statistically significant increases in aspirin use were non-Hispanic Blacks and those with less than high school education, both for primary and secondary CVD prevention.

The aim of this study was to provide an epidemiological analysis of the use of low-dose aspirin for primary and secondary CVD prevention based on the most recently available data. However, there are some
important limitations. The NHIS is designed to be as representative as possible, yet there are inherent difficulties in extrapolating to national estimates from relatively small sample sizes. Also, this study was based on self-report data, which can be subject to inaccuracies due to recall bias, social desirability bias, and errors in self-observation (Hawkshead and Krousel-Wood, 2007; Gagné and Godin, 2005; Turner, 2002; Farmer, 1999; La Fleur, 2004) especially regarding behaviors and risk factors relating to CVD and cancer (Mainous et al., 2014; Newell et al., 1999). To combat this, the NCHS conducts question evaluation studies in order to test and develop survey questions through the Questionnaire Design Research Laboratory (QDRL). The QDRL leads studies to identify and define patterns of question interpretation, types of response error, and potential for bias in cross-national or cross-cultural population data (Centers for Disease Control and Prevention, 2016). Other potential limitations include being restricted only to adults over 40 years of age and not including data on other types of cardiovascular disease such as aortic aneurysms or peripheral arterial disease.

Despite these potential limitations, the results of this study provide greater detail on the use of aspirin in the general population for both primary and secondary CVD prevention. Of particular note is the fact that this study used the most current four years of available data to provide insight into recent changes in the primary and secondary CVD prevention populations, rather than a cross-sectional snapshot. To our knowledge this is the first epidemiological study to investigate trends in aspirin usage. Based on our results, although the prevalence of aspirin usage remains high, with over 30% of adults over 40 years of age taking aspirin for primary or secondary CVD prevention, this proportion has decreased in recent years.

Conflict of interest

Financial support for this research was funded by Deerfield Management, a healthcare investment firm dedicated to advancing healthcare through investment, information and philanthropy. The funder provided support in the form of salaries for the authors, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

Baigent, C., Blackwell, L., Collins, R., et al., 2009. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860. http://dx.doi.org/10.1016/S0140-6736(09)60503-1.

Bibbins-Domingo, K., US Preventive Services Task Force, 2016. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. preventive services task force recommendation statement. Ann. Intern. Med. 164:836–845. http://dx.doi.org/10.7326/M16-0577.

Bieler, G.S., Brown, G.G., Williams, R.L., Brogan, D.J., 2010. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am. J. Epidemiol. 171:618–623. http://dx.doi.org/10.1093/aje/kwp440.

Centers for Disease Control and Prevention, 2016. Questionnaire Design Research Laboratory (QDRL). http://www.cdc.gov/qdrl/ (Available from, 6 September).

Fang, J., George, M.G., Gindi, R.M., et al., 2015. Use of low-dose aspirin as secondary prevention of atherosclerotic cardiovascular disease in US adults (from the National Health Interview Survey, 2012). Am. J. Cardiol. 115:895–900. http://dx.doi.org/10.1016/j.amjcard.2015.01.014.

Farmer, K.C., 1999. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin. Ther. 21:1074–1900. http://dx.doi.org/10.1016/S0149-2918(99)80026-5.

Fuster, V., Sweeny, J.M., 2011. Aspirin: a historical and contemporary therapeutic overview. Circulation 123:768–778. http://dx.doi.org/10.1161/CIR.0b013e3182118072.

Gagné, C., Godin, G., 2005. Improving self-report measures of non-adherence to HIV medications. Psychol. Health 20:803–816. http://dx.doi.org/10.1080/0887044050088441.

Hawkshead, J., Krousel-Wood, M.A., 2007. Techniques for measuring medication adherence in hypertensive patients in outpatient settings: advantages and limitations. Dis. Manag. Health Out. 15:109–118. http://dx.doi.org/10.2165/00115677-200715020-00006.

Ittman, S., VaelWormer, J., Rezkalla, S., 2014. The role of aspirin in the prevention of cardiovascular disease. Clin. Med. Res. 12:147–154. http://dx.doi.org/10.3121/cmr.2013.1197.

Klein, R.J., Schoenborn, C.A., 2001. Age Adjustment Using the 2000 Projected US Population. Healthy People Statistical Notes No. 20. National Center for Health Statistics, Hyattsville, MD.

La Fleur, J., 2004. Methods to measure patient compliance with medication regimens. J. Pain Palliat. Care Pharmacother. 18, 81–87.

Mainous, A.G., Tanner, R.J., Shorr, R.I., Lumacher, M.C., 2014. Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011–2012. J. Am. Heart Assoc. 3, e000989. http://dx.doi.org/10.1161/JAHA.114.000989.

Miner, J., Hofftines, A., 2007. The discovery of aspirin’s antithrombotic effects. Tex. Heart Inst. J. 34, 179–186.

MozaFarian, D., Benjamin, E.J., Go, A.S., et al., 2016. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133: 100. http://dx.doi.org/10.1161/CIR.0000000000000350.

National Center for Health Statistics, 2016. About the National Health Interview Survey. http://www.cdc.gov/nchs/about_nhis.htm (Available from, 1 September).

Newell, S.A., Girgis, A., Sanson-Fisher, R.W., Savolainen, N.J., 1999. The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am. J. Prev. Med. 17, 211–229.

Parsons, V.L., Mortarality, C., Jonas, K., et al., 2014. Design and estimation for the National Health Interview Survey, 2006–2015. Vital Health Stat. 1–53.

Saylor, J., Friedmann, E., Lee, H.J., 2012. Navigating complex sample analysis using national survey data. Nurs. Res. 61:231–237. http://dx.doi.org/10.1097/NUR.0b013e3182533403.

Smith Jr., S.C., Benjamin, E.J., Bonow, R.O., et al., 2011. AHA/ACC secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the world heart federation and the preventive cardiovascular nurses association. J. Am. Coll. Cardiol. 58: 2432–2446. http://dx.doi.org/10.1016/j.jacc.2011.10.024.

Turner, B., 2002. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J. Infect. Dis. 185 (Suppl. 2):S148–S155. http://dx.doi.org/10.1086/340117.

United States Census Bureau, 2016. Population Projections. http://www.census.gov/popest/projections/data/national/2014/summarytables.html (Available from, 6 September).

World Health Organization, 2016. BMI Classification. http://apps.who.int/bmi/index.jsp?introPage=intro_3.html (Available from, 6 September).